TY - JOUR
T1 - Health-related quality of life in survivors of septic shock
T2 - 6-month follow-up from the ADRENAL trial
AU - the ADRENAL Trial Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group
AU - Hammond, Naomi E.
AU - Finfer, Simon R.
AU - Li, Qiang
AU - Taylor, Colman
AU - Cohen, Jeremy
AU - Arabi, Yaseen
AU - Bellomo, Rinaldo
AU - Billot, Laurent
AU - Harward, Meg
AU - Joyce, Christopher
AU - McArthur, Colin
AU - Myburgh, John
AU - Perner, Anders
AU - Rajbhandari, Dorrilyn
AU - Rhodes, Andrew
AU - Thompson, Kelly
AU - Webb, Steve
AU - Venkatesh, Balasubramanian
AU - Cowdrey, Keri Anne
AU - Gilder, Eileen
AU - Long, Stephanie
AU - McCarthy, Lianne
AU - McGuinness, Shay
AU - Parke, Rachael
AU - Benefield, Kristen
AU - Chen, Yan
AU - McConnochie, Rachael
AU - Newby, Lynette
AU - Eastwood, Glenn
AU - Jones, Daryl
AU - Peck, Leah
AU - Young, Helen
AU - Boschert, Catherine
AU - Edington, John
AU - Wright, Stephen
AU - Stewart, Antony
AU - Thomas, Peter
AU - Baker, Stuart
AU - Moore, John
AU - Rose, Steve
AU - Bamford, Amy
AU - Pemberton, Philip
AU - Snelson, Catherine
AU - Whitehouse, Tony
AU - White, Jonathan
AU - Cooper, David
AU - Allen, Chris
AU - Coles, Jennifer
AU - Smith, John
AU - Davis, Michael
N1 - Publisher Copyright:
© 2020, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Purpose: To investigate the impact of hydrocortisone treatment and illness severity on health-related quality of life (HRQoL) at 6 months in septic shock survivors from the ADRENAL trial. Methods: Using the EuroQol questionnaire (EQ-5D-5L) at 6 months after randomization we assessed HRQoL in patient subgroups defined by hydrocortisone or placebo treatment, gender, illness severity (APACHE II < or ≥ 25), and severity of shock (baseline peak catecholamine doses < or ≥ 15 mcg/min). Additionally, in subgroups defined by post-randomisation variables; time to shock reversal (days), treatment with renal replacement therapy (RRT), and presence of bacteremia. Results: At 6 months, there were 2521 survivors. Of these 2151 patients (85.3%-1080 hydrocortisone and 1071 placebo) completed 6-month follow-up. Overall, at 6 months the mean EQ-5D-5L visual analogue scale (VAS) was 70.8, mean utility score 59.4. Between 15% and 30% of patients reported moderate to severe problems in any given HRQoL domain. There were no differences in any EQ-5D-5L domain in patients who received hydrocortisone vs. placebo, nor in the mean VAS (p = 0.6161), or mean utility score (p = 0.7611). In all patients combined, males experienced lower pain levels compared to females [p = 0.0002). Neither higher severity of illness or shock impacted reported HRQoL. In post-randomisation subgroups, longer time to shock reversal was associated with increased problems with mobility (p = < 0.0001]; self-care (p = 0.0.0142), usual activities (p = <0.0001] and pain (p = 0.0384). Amongst those treated with RRT, more patients reported increased problems with mobility (p = 0.0307) and usual activities (p = 0.0048) compared to those not treated. Bacteraemia was not associated with worse HRQoL in any domains of the EQ-5D-5L. Conclusions: Approximately one fifth of septic shock survivors report moderate to extreme problems in HRQoL domains at 6 months. Hydrocortisone treatment for septic shock was not associated with improved HRQoL at 6 months. Female gender was associated with worse pain at 6 months.
AB - Purpose: To investigate the impact of hydrocortisone treatment and illness severity on health-related quality of life (HRQoL) at 6 months in septic shock survivors from the ADRENAL trial. Methods: Using the EuroQol questionnaire (EQ-5D-5L) at 6 months after randomization we assessed HRQoL in patient subgroups defined by hydrocortisone or placebo treatment, gender, illness severity (APACHE II < or ≥ 25), and severity of shock (baseline peak catecholamine doses < or ≥ 15 mcg/min). Additionally, in subgroups defined by post-randomisation variables; time to shock reversal (days), treatment with renal replacement therapy (RRT), and presence of bacteremia. Results: At 6 months, there were 2521 survivors. Of these 2151 patients (85.3%-1080 hydrocortisone and 1071 placebo) completed 6-month follow-up. Overall, at 6 months the mean EQ-5D-5L visual analogue scale (VAS) was 70.8, mean utility score 59.4. Between 15% and 30% of patients reported moderate to severe problems in any given HRQoL domain. There were no differences in any EQ-5D-5L domain in patients who received hydrocortisone vs. placebo, nor in the mean VAS (p = 0.6161), or mean utility score (p = 0.7611). In all patients combined, males experienced lower pain levels compared to females [p = 0.0002). Neither higher severity of illness or shock impacted reported HRQoL. In post-randomisation subgroups, longer time to shock reversal was associated with increased problems with mobility (p = < 0.0001]; self-care (p = 0.0.0142), usual activities (p = <0.0001] and pain (p = 0.0384). Amongst those treated with RRT, more patients reported increased problems with mobility (p = 0.0307) and usual activities (p = 0.0048) compared to those not treated. Bacteraemia was not associated with worse HRQoL in any domains of the EQ-5D-5L. Conclusions: Approximately one fifth of septic shock survivors report moderate to extreme problems in HRQoL domains at 6 months. Hydrocortisone treatment for septic shock was not associated with improved HRQoL at 6 months. Female gender was associated with worse pain at 6 months.
KW - EQ5D
KW - Health-related quality of life
KW - Intensive care
KW - Sepsis
KW - Septic shock
KW - Steroids
UR - https://www.scopus.com/pages/publications/85090509268
U2 - 10.1007/s00134-020-06169-1
DO - 10.1007/s00134-020-06169-1
M3 - Article
C2 - 32676679
AN - SCOPUS:85090509268
SN - 0342-4642
VL - 46
SP - 1696
EP - 1706
JO - Intensive Care Medicine
JF - Intensive Care Medicine
IS - 9
ER -